Back to Treatments

Treatment

Brolucizumab

1
Conditions
50
Trials
8,000
Participants
35%
Average Safety

Condition Evidence

Macular Degeneration

50 trials · 8,000 participants

85% effectiveness · 35% safety
Brolucizumab | DFDA